Abstract

In recent years, cancer therapy has advanced from chemotherapy and targeted therapy to immunotherapy, thus resolving drug specificity-related problems pertaining to tumor cells and resistance. Chimeric antigen receptor (CAR) T cells are genetically modified T cells that express receptors for specific tumor cell antigens to induce T-cell-mediated cytotoxicity. Therefore, the identification of specific antigens on tumor cells is a key point that should be considered in CAR T-cell therapy. For instance, Epstein-Barr virus expresses the oncoprotein latent membrane protein 1 to induce various diseases such as nasopharyngeal carcinoma; posttransplant lymphoproliferative disorders; and diffuse large B-cell, Burkitt, and Hodgkin lymphomas.